Kenya has officially fired the first shot in a historic industrial overhaul—one that could end decades of reliance on imported medicines and usher in a new era of homegrown pharmaceutical power.
At a high-level Pharmaceutical Manufacturing Investors’ Breakfast in Nairobi, leaders from government, industry and the health sector delivered a united call: Kenya must produce what it consumes. And the country is now moving decisively to reclaim its pharmaceutical sovereignty.
In a move seen as a national security and economic turning point, the government endorsed an ambitious agenda to transition from import-heavy consumption—currently above 70%—to a locally anchored pharmaceutical manufacturing ecosystem.
Themed “Paradigm Shift: From Importation to Local Manufacturing of Pharmaceutical Products,” the event brought together investors, policymakers and industry captains, all aligned on one message:
Local manufacturing is not optional—it is Kenya’s next frontier for jobs, growth, and health security.
Cabinet Secretary for Investments, Trade and Industry Hon. Lee Kinyanjui set the tone for the day:
“We will work closely with the Ministry of Health to ensure uptake of locally produced products, timely payment, and the removal of any regulatory or legal barriers that hinder growth.”
Kinyanjui emphasized that pharmaceuticals are central to the country’s industrialization blueprint and a key pillar in stabilizing the economy amid forex pressures.
Kenya imports more than 70% of its medicines, exposing the country to:
Dollar volatility and forex strain
Unpredictable global supply chains
Higher drug prices
Risk of shortages during crises
Principal Secretary for Investment Promotion Abubakar Hassan Abubakar warned that the current model is unsustainable, noting that Kenya aims to produce at least 60% of its medicines locally in the coming years.
Policy incentives, Special Economic Zones, and targeted investment pipelines will form the backbone of this shift.
State Department for Medical Services PS, Dr. Ouma Oluga, unpacked the structural challenges slowing the sector:
High importation of raw materials
Costly financing
Slow technology transfer
Regulatory bottlenecks
He called for bold and coordinated reforms:
“By addressing financing gaps, regulatory hurdles, and technology barriers, we can create jobs, save foreign exchange, and enhance access to quality healthcare.”
In one of the day’s most consequential announcements, the Kenya Development Corporation (KDC) revealed plans to deploy long-term financing and equity instruments tailored to the pharmaceutical industry.
KDC Director General Norah Ratemo stressed that manufacturers need patient, stable capital—not short-term commercial loans that stifle growth.
Manufacturers were invited to submit proposals for equity and debt financing targeting high-impact areas that can rapidly boost Kenya’s production capacity.
The Pharmaceutical Society of Kenya (PSK) delivered a powerful message:
“A country that cannot produce essential medicines cannot secure its population.”
PSK President Dr. Wairimu Njuki urged the government to treat pharmaceuticals with the same strategic weight as energy, food, and defence.
Through its EPIC pillars—Education, Policy, Innovation, Collaboration—the Society committed to deepening Kenya’s manufacturing readiness through:
Workforce development
Quality assurance
Technology adoption
Research and innovation partnerships
BioVax CEO Dr. Wesley Rono reaffirmed Kenya’s alignment with Africa’s plan to produce 60% of vaccines locally by 2040.
“At BioVax, we are turning this goal into action; building capabilities and technologies that will position Kenya as a regional biotechnology hub.”
BioVax is expected to anchor Kenya’s vaccine manufacturing ambitions, reducing reliance on foreign suppliers.
The meeting ended with strong consensus:
Kenya’s pharmaceutical future must be built locally—competitively, sustainably, and collaboratively.
With financing reforms underway, supportive policy direction, and a coalition of government and private partners, Kenya is moving from:
Buyer to manufacturer
Consumer to producer
Dependence to sovereignty
Kenya is choosing production over importation, resilience over vulnerability, and innovation over dependency.
The blueprint is clear.
The momentum is strong.
The era of Kenyan-made medicines has begun.
Leave a Reply